Vaccitech Doses First Patient in HPV001, a Phase 1/2 Clinical Trial of VTP-200 Immunotherapeutic for High-risk Persistent HPV Infection

March 19, 2021

Stay up to date

Get the latest on cutting-edge developments in our portfolio, straight to your inbox.